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NASA Technology
In a 1962 speech, President John F. Kennedy said, “We choose to go to the Moon in this decade and do the other things, not because they are 
easy, but because they are hard, because that goal will 
serve to organize and measure the best of our energies 
and skills.” And what a feat of engineering it was in 
1969 when, after 4 days and 239,000 miles of rocket-
powered thrust, NASA’s lunar module landed on the 
Moon’s surface, turning an important page in human-
kind’s progress. 
Fast-forward to 2013, and the space agency has its 
sights set on another lofty goal: a manned landing on 
the Red Planet. “‘A human mission to Mars is today the 
ultimate destination in our solar system for humanity, 
and it is a priority for NASA,” said NASA Administrator 
Charles Bolden in a recent speech. 
And what a page-turner that will be. Based on 
current technology, the best estimate is that it will take 
crewmembers 7-10 months before they land on Martian 
soil. For comparison, the Mars Curiosity rover took more 
than 8 months to complete its 352 million-mile flight 
path. And while the Curiosity mission is a marvel of 
engineering, a mission that sends humans to Mars will be 
an even larger challenge, because many innovations will 
have to be developed to ensure that astronauts have the 
necessary tools to survive what could be years 
spent in space. 
One aspect critical to an astro-
naut’s long-term survival away 
from Earth is effective and 
efficient health-moni-
toring technologies. 
In space, there are 
no laboratories 
that can analyze 
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blood samples in order to check for possible diseases 
or deficiencies. 
In 2003, NASA scientists were already looking for a 
device that in one reading could register red and white 
blood cell counts as well as other substances, such as 
electrolytes, hormones, and other molecules. It also 
needed to be conducive to use in space. “We needed 
something that was miserly in terms of the resources 
it required, had a long shelf life, and was very light, 
adaptable, and portable,” says Emily Nelson, a senior 
research engineer at Glenn Research Center. 
Unable to find anything “off the shelf” that fit the bill, 
Nelson says, “We came to realize we needed something 
specially designed to meet our requirements, so we 
identified our essential requirements and broadcast a call 
for solicitations.”
Technology Transfer 
Answering the call was Cambridge, Massachusetts-
based DNA Medicine Institute Inc. (DMI). Founded in 
2008, the company specializes in developing innovative 
medical devices, and NASA’s solicitation fell within 
its expertise. That year, Glenn awarded Small Business 
Innovation Research (SBIR) funding to the firm, which 
went on to design the Reusable Handheld Electrolyte 
and Lab Technology for Humans (rHEALTH) sensor. 
It’s a compact, portable device that utilizes a battery 
of technologies to measure all of the substances NASA 
needed to monitor, in addition to other biomarkers. 
(A biomarker is any measurable substance in the body 
that can indicate various conditions; for example, a high 
antibody count might indicate an infection.)
The first critical components of the device are the 
microfluidic handling units, which are tiny channels 
that prepare the drawn blood for analysis by moving it 
through the device, which performs a series of tasks such 
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An artist’s rendition of an 
astronaut gathering samples 
on the surface of Mars. 
Long-term space missions 
would require that astronauts 
have access to remote health 
monitoring devices, like the 
Reusable Handheld Electrolyte 
and Lab Technology for 
Humans (rHEALTH) sensor.
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as separating, diluting, and mixing various constituents. 
But unlike conventional blood tests, which use cartridges 
that must be discarded after every test, the rHEALTH 
sensor’s units, in addition to being more efficient, are also 
reusable, which cuts down on both costs and the volume 
of material that needs to be brought into space. Next is 
the device’s novel use of optical fluorescence technology, 
which can singlehandedly measure biomarkers, 
electrolytes, and analytes (biochemical substances) and 
also performs cell counts. The substance in question will 
glow if it’s in the sample, and its fluorescent intensity 
indicates how much of it is present. 
The third major component of the technology is an 
example of big things coming in small packages. It was 
developed through separate SBIR contracts, the first of 
which was awarded the following year. In that round 
of solicitations, NASA Glenn sought proposals for a 
technology that had the potential to perform a massive 
number of tests simultaneously on a single blood sample, 
which no product on the market could do at the time. 
DMI answered the call with its nanostrip reagents. 
“They’re kind of similar to urine analysis or pH test 
strips where you have a series of different pads for sensing 
analytes,” says Eugene Chan, the company’s founder 
and president. “The big difference is we’ve shrunk that 
technology over a billion-fold in volume so that we can 
implement that at the blood cell level.” Each individual 
nanostrip can perform a panel of blood tests, and it is also 
encoded with a fluorescent tag, similar to a bar code, that 
identifies which set of analytes are being measured. A set 
of multisensor nanostrips could then measure hundreds 
of biomarkers or more from one blood sample. 
Nelson says the innovation is a game changer. “Once 
it’s fully developed, the DMI technology could permit 
more blood tests per sample than anything on the 
market,” she says. “It would also allow greater flexibility 
to define the types of tests that would be done, whether 
they are routine blood panels or novel biomarkers that 
are used for cutting-edge research. Chan’s pioneering 
innovations could bring revolutionary new capabilities 
to medical diagnosis and treatment, whether that’s in a 
clinical setting or in the emergency room or in space.”
Benefits 
With its low mass, efficiency, and versatility, the 
rHEALTH sensor is vying with other recently developed 
portable diagnostic devices for the right to be used for 
space medical research onboard the International Space 
Station (ISS). Scientists would like to collect data on 
dozens of biomarkers on the ISS to help better 
understand some of the biggest medical concerns 
for long-duration spaceflight, including 
immune dysregulation, bone loss, muscle 
atrophy, kidney stone formation, and 
visual dysfunction. The sensor has 
already been proven to work in 
microgravity simulations following 
tests done on parabolic flights, 
which mimic the weightlessness 
of space. 
The rHEALTH sensor is 
also currently available for pur-
chase by universities and research 
centers, and within the next year the 
company is expecting to get the product approved by the 
Federal Drug Administration for use in hospitals, clin-
ics, and even homes. “We want to provide information 
for the masses,” Chan says. “With the device, people can 
measure their insulin levels, thyroid hormone and cho-
lesterol levels, practically anything. And beyond just the 
variety of measurements is the time factor; from pin prick 
to results spans all of two minutes.”
“A lot of times you don’t want to wait for the central 
lab to get the information back to you,” Chan says, “or 
you might be in space where there’s no central lab or in 
the field somewhere in the middle of Africa. Having this 
high-powered test in the palm of your hand is what this 
is really all about.” 
This technology is made possible, Chan says, with 
support from a forward-thinking agency such as NASA. 
“It takes that space-age kind of thinking to develop some-
thing that’s a breakthrough,” he says. “Ever since they’ve 
[NASA] demonstrated an interest in this, the general 
field has picked up. The Agency has really galvanized the 
whole sector.” v
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The rHEALTH sensor 
utilizes nanostrip 
technology to analyze 
dozens of biomarkers 
simultaneously. The device was 
also designed with efficiency and 
reusability in mind. 
